Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nasal delivery
Pharma
ARS inks ex-US licensing pact for Neffy worth up to $465M
ARS will receive up to $465 million in a new licensing pact with ALK-Abelló to sell its epinephrine nasal spray Neffy in certain ex-U.S. territories.
Fraiser Kansteiner
Nov 11, 2024 9:44am
AZ's FluMist wins FDA nod as first self-administered flu vaccine
Sep 20, 2024 3:24pm
ARS hits major setback in bid to launch epinephrine newcomer
Sep 20, 2023 10:31am
Orexo seeks approval of nasal high-dose opioid rescue medicine
Feb 7, 2023 8:40am
Aptar creates metal-free nasal spray pump to boost recyclability
Jan 31, 2023 11:59am
Nasal delivery gets antibody to rodent brains to treat stroke
Jan 24, 2023 6:40am
